{"count": 3, "results": [{"_id": "34370970", "pmid": 34370970, "title": "Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.", "journal": "Lancet", "authors": ["Ludvik B", "Giorgino F", "Jódar E", "Frias JP", "Fernández Landó L", "Brown K", "Bray R", "Rodríguez Á"], "date": "2021-08-14T00:00:00Z", "doi": "10.1016/S0140-6736(21)01443-4", "meta_date_publication": "2021 Aug 14", "meta_volume": "398", "meta_issue": "10300", "meta_pages": "583-598", "score": 50248.945, "text_hl": "Once-weekly tirzepatide versus once-daily insulin degludec as add-on to @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ with or without SGLT2 inhibitors in @SPECIES_9606 @@@patients@@@ with @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@type 2 diabetes@@@ (@<m>DISEASE_Hypomagnesemia_primary</m> @DISEASE_MESH:C537153 @@@SURPASS-3@@@): a randomised, open-label, parallel-group, phase 3 trial.", "citations": {"NLM": "Ludvik B, Giorgino F, Jódar E, Frias JP, Fernández Landó L, Brown K, Bray R, Rodríguez Á. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021 Aug 14;398(10300):583-598. PMID: 34370970", "BibTeX": "@article{34370970, title={Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.}, author={Ludvik B and Giorgino F and Jódar E and Frias JP and Fernández Landó L and Brown K and Bray R and Rodríguez Á}, journal={Lancet}, volume={398}, number={10300}, pages={583-598}}"}}, {"_id": "37695982", "pmid": 37695982, "pmcid": "PMC10713140", "title": "Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer", "journal": "J Clin Oncol", "authors": ["Goodwin PJ", "Chen BE", "Gelmon KA", "Whelan TJ", "Ennis M", "Lemieux J", "Ligibel JA", "Hershman DL", "Mayer IA", "Hobday TJ", "Bliss JM", "Rastogi P", "Rabaglio-Poretti M", "Thompson AM", "Rea DW", "Stos PM", "Shepherd LE", "Stambolic V", "Parulekar WR"], "date": "2023-09-11T00:00:00Z", "doi": "10.1200/JCO.23.00296", "meta_date_publication": "2023 Sep 11", "meta_volume": "", "meta_issue": "", "meta_pages": "JCO2300296", "score": 50245.297, "text_hl": "Between 2010 and 2013, 3,649 @SPECIES_9606 @@@patients@@@ with @DISEASE_Breast_Neoplasms @DISEASE_MESH:D001943 @@@breast cancer@@@ younger than 75 years without @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes@@@ with high-risk @DISEASE_Nemaline_myopathy_5 @DISEASE_MESH:C538397 @@@T1@@@-3, @<m>DISEASE_Hypomagnesemia_primary</m> @DISEASE_MESH:C537153 @@@N0-3@@@ M0 @DISEASE_Breast_Neoplasms @DISEASE_MESH:D001943 @@@breast cancer@@@ (any @GENE_ESR1 @GENE_2099 @@@estrogen receptor@@@, @GENE_PGR @GENE_5241 @@@progesterone receptor@@@, @GENE_ERBB2 @GENE_2064 @@@human epidermal growth factor receptor 2@@@) were randomly assigned to @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ 850 mg orally twice a day or placebo twice a day for 5 years. ", "citations": {"NLM": "Goodwin PJ, Chen BE, Gelmon KA, Whelan TJ, Ennis M, Lemieux J, Ligibel JA, Hershman DL, Mayer IA, Hobday TJ, Bliss JM, Rastogi P, Rabaglio-Poretti M, Thompson AM, Rea DW, Stos PM, Shepherd LE, Stambolic V, Parulekar WR. Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer J Clin Oncol. 2023 Sep 11;():JCO2300296. PMID: 37695982", "BibTeX": "@article{37695982, title={Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer}, author={Goodwin PJ and Chen BE and Gelmon KA and Whelan TJ and Ennis M and Lemieux J and Ligibel JA and Hershman DL and Mayer IA and Hobday TJ and Bliss JM and Rastogi P and Rabaglio-Poretti M and Thompson AM and Rea DW and Stos PM and Shepherd LE and Stambolic V and Parulekar WR}, journal={J Clin Oncol}, pages={JCO2300296}}"}}, {"_id": "22793669", "pmid": 22793669, "title": "Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US.", "journal": "J Med Econ", "authors": ["Samyshkin Y", "Guillermin AL", "Best JH", "Brunell SC", "Lloyd A"], "date": "2012-01-01T00:00:00Z", "doi": "10.3111/13696998.2012.708691", "meta_date_publication": "2012", "meta_volume": "15 Suppl 2", "meta_issue": "", "meta_pages": "6-13", "score": 50036.8, "text_hl": "The model was populated using @SPECIES_9606 @@@patient@@@ characteristics (mean age: 57.9 years; mean @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes@@@ duration: 7.9 years; mean HbA1(c): 8.3%; mean body mass index [BMI]: 32.3 kg/m(2)) and clinical data from a phase 3 clinical trial that compared EQW with @CHEMICAL_Insulin_Glargine @CHEMICAL_MESH:D000069036 @@@IG@@@ in @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@T2DM@@@ @SPECIES_9606 @@@patients@@@ on a background of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ alone or a combination of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ and a @CHEMICAL_Sulfonylurea_Compounds @CHEMICAL_MESH:D013453 @@@sulphonylurea@@@ (@<m>DISEASE_Hypomagnesemia_primary</m> @DISEASE_MESH:C537153 @@@DURATION-3@@@). ", "citations": {"NLM": "Samyshkin Y, Guillermin AL, Best JH, Brunell SC, Lloyd A. Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US. J Med Econ. 2012;15 Suppl 2():6-13. PMID: 22793669", "BibTeX": "@article{22793669, title={Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US.}, author={Samyshkin Y and Guillermin AL and Best JH and Brunell SC and Lloyd A}, journal={J Med Econ}, volume={15 Suppl 2}, pages={6-13}}"}}]}